Streamline your patent due diligence with deep analytics for patents, inventors, and attorneys



Compare patents by technology sector



Deep Analytics



Quickly evaluate patents of interest

► Want to see more? Join for free!

PatentQuant Patent Profile
Generated February 19, 2018

Pharmaceutical composition

Patent Number: 5,610,193

Patent Information

Abstract
A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.
Patent Number: 5,610,193
Issue Date: 1997-03-11

Primary Category

Biographical Information

Executive Summary

Summary

This patent was granted in ► Log In, which is ► Log In speed.

It has ► Log In claims, which is ► Log In than average for this category.

Its proximity to basic research is ► Log In than others in this category, and it displays ► Log In technology cycle time.

This patent received ► Log In citations from other patents, and references ► Log In other patents, as compared to other patents in this category.

Grant Time

► Log In

Claims

► Log In

► Want to see more? Join for free!

PatentStat Scores in Not categorized
These scores show the percentile ranks for each metric.
For example, a score of 90 means that 90% of similar patents had lower scores.

Patent Grant Time

This patent had ► Log In grant time compared to others in this category.

Patent grant time can be influenced by many factors. Activities within the USPTO that are beyond the control of patent attornies can influence grant time, but short grant times can also indicate well-written patents and dedicated efforts to respond rapidly to USPTO office actions with strong arguments. Shorter grant times are preferable, and the scores for this section are inverse measures — higher scores are better.

Patent Claims

This patent has ► Log In claims compared to others in this category.

The number of claims in a patent is correlated with its strength. Because greater claim counts increase the cost of a patent, more claims can indicate the importance an applicant assigns to a patent. Importantly, some may elect to file claims across multiple patents. A higher score in this metric indicates more claims, relative to others in this category.

Citations From Other Patents

This patent has received ► Log In citations from other patents, than others in this category.

Citations from other patents are an important measure of the significance of a patent. More citations indicate that other technologies build on a patent. Higher scores in this metric are better, and indicate more citations from other patents.

Citations to Other Patents

This patent referenced ► Log In citations to other patents, than others in this category.

A lower number of citations to other patents can be a sign of diminished patent strength. More citations indicate dependence on more other technologies. Higher scores in this category are better, and indicate fewer citations to other patents.

Research and Innovation Indicators
These are percentile ranks — they indicate the percentage of peers with lower scores.

Proximity to Basic Research

► Log In

0%

Proximity to Basic Research

This patent has ► Log In proximity to basic research compared to others in this category.

Proximity to basic research is measured by comparing the number of citations to non-patent literature among a cohort of patents. Because most non-patent citations are primary research papers, a higher count indicates greater proximity to basic research.

► Want to see more? Join for free!

Citations

Patents that cite this patent

Patent Title
9,107,830 Inhibitors of crystallization in a solid dispersion
9,096,556 Amorphous ritonavir co-precipitated
9,023,393 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
8,759,353 Co-crystals and pharmaceutical compositions comprising the same
8,703,199 Pharmaceutical compositions of adsorbates of amorphous drug
8,691,878 Solid pharmaceutical dosage form
8,575,208 Inhibitors of serine proteases
8,529,882 Peptidomimetic protease inhibitors
8,492,546 Co-crystals and pharmaceutical compositions comprising the same
8,470,347 Self-emulsifying active substance formulation and use of this formulation
8,440,706 Inhibitors of serine proteases
8,399,015 Solid pharmaceutical dosage form
8,389,006 Pharmaceutical compositions of adsorbates of amorphous drug
8,377,952 Solid pharmaceutical dosage formulation
8,372,873 Inhibitors of serine proteases
8,372,846 Co-crystals and pharmaceutical compositions comprising the same
8,333,990 Solid pharmaceutical dosage form
8,314,141 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
8,309,613 Solid pharmaceutical dosage form
8,298,579 Tamper resistant dosage form comprising an adsorbent and an adverse agent
8,268,349 Solid pharmaceutical dosage form
8,252,923 Peptidomimetic protease inhibitors
8,247,532 Deuterated hepatitis C protease inhibitors
8,217,048 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
8,197,829 Self-emulsifying active substance formulation and use of this formulation
8,039,475 Co-crystals and pharmaceutical compositions comprising the same
8,025,899 Solid pharmaceutical dosage form
7,985,762 Inhibitors of serine proteases
7,964,624 Inhibitors of serine proteases
7,820,671 Peptidomimetic protease inhibitors
7,364,752 Solid dispersion pharamaceutical formulations

► Want to see more? Join for free!

Information presented on this site is collected from the USPTO and other sources. Errors may have been introduced in the original assembly or analysis of the data.
No warranties are expressed or implied.The content of this site is not a substitute for skilled legal, financial, or other guidance.
Copyright thinkBiotech LLC. All rights reserved.
Privacy policy.
`abc